Bio-Bridge Science Signs Exclusive Distribution Agreement with Xinhua Surgical Instruments
22 November 2005 - 2:53AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB: BGES) today announced that it has
entered into an exclusive distribution agreement with Xinhua
Surgical Instruments Co., Ltd., located in Shandong, China. Under
the agreement, Bio-Bridge Science has been granted exclusive
distribution rights for all Xinhua surgical instruments in the
United States, which are subject to FDA approval. Dr. Liang Qiao,
Chairman and CEO of Bio-Bridge Science said, "We believe that our
agreement with Xinhua will enable us to create a revenue stream as
we develop our vaccine program. We are pleased to be able to offer
Xinhua surgical instruments to potential U.S. customers. Xinhua
surgical instruments are manufactured with German technology and
expertise, giving them competitive advantages in product surface,
corrosion resistance, performance, as well as price. We believe our
knowledge of the Chinese and American medical market should allow
us to be effective in introducing the products in the United
States." About the Company Bio-Bridge Science, Inc. is a
biotechnology firm focused on the development of vaccines with
broad therapeutic and preventive applications. Through its wholly
owned subsidiary in Beijing, Bio-Bridge is developing a HIV
Vaccine, that is expected to enter clinical trials early next year
in China. The vaccine, based on exclusive technology co-developed
by CEO Liang Qiao, an associate professor at Loyola University
Chicago's Stritch School of Medicine, is designed to target
infection in mucosal tissues, the first type of tissue attacked by
HIV. About Xinhua Xinhua Surgical Instruments Co. Ltd. is a world
leader in surgical instrument production that is based in Shandong,
China Forward Looking Statements This press release contains
forward-looking statements as defined by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information and
accompanying notes to financial statements.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bio Bridge Science Inc (CE) (OTCMarkets): 0 recent articles
More Bio-Bridge Science, Inc. News Articles